On April 12th, Altimmune (ALT) presented Phase I HepTcell data at the International Liver Congress in Vienna, Austria. Altimmune's immunotherapeutic synthetic peptide vaccine candidate demonstrated admirable safety and justified the company's plan to move into a Phase II study. Admittedly, I have never been a huge fan of the HepTcell program for several reasons, one of which is Altimmune's competition for HBV. In addition, the HepTcell program has had a rough time with data readouts and has been the cause of some stock sell-offs. I was hopeful the recent clarification on the "bad"